NCT05715398View on ClinicalTrials.gov

BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

BR790+anlotinib

BR790 will be administered orally, variable dose on Day 1 of each 21-day cycle， Anlotinib will be administered as PO fixed dose on Day1-14 of each 21-day cycle

All Listed Sponsors
lead

Shanghai Gopherwood Biotech Co., Ltd.

INDUSTRY

NCT05715398 - BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter